 SOUTH SAN FRANCISCO, Calif., Oct. 12, 2021 GLOBE NEWSWIRE -- Satsuma Pharmaceuticals, Inc. Nasdaq: STSA, a clinical-stage biopharmaceutical company developing STS101 dihydroergotamine DHE nasal powder, a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced the appointment of Mutya Harsch, JD to its Board of Directors, effective immediately. Ms. Harsch is a highly regarded and established pharmaceutical industry professional who brings over 20 years of legal, corporate governance, corporate transaction, and operating experience to Satsuma. She currently serves as General Counsel, Chief Legal Officer and Secretary of VYNE Therapeutics, a publicly traded biopharmaceutical company. 